Cargando…
METTL14 Acts as a Potential Regulator of Tumor Immune and Progression in Clear Cell Renal Cell Carcinoma
Clear cell renal cell carcinoma (ccRCC) is characterized by its insensitivity to chemoradiotherapy and lacks effective diagnostic and prognostic biomarkers. In this study, we focused on the role of m6A RNA methylation regulators for tumor immunity. Based on the expression of 20 m6A regulators, conse...
Autores principales: | Xu, Tianbo, Gao, Su, Ruan, Hailong, Liu, Jingchong, Liu, Yuenan, Liu, Di, Tong, Junwei, Shi, Jian, Yang, Hongmei, Chen, Ke, Zhang, Xiaoping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194313/ https://www.ncbi.nlm.nih.gov/pubmed/34122497 http://dx.doi.org/10.3389/fgene.2021.609174 |
Ejemplares similares
-
A Novel Ferroptosis-Related Pathway for Regulating Immune Checkpoints in Clear Cell Renal Cell Carcinoma
por: Gao, Su, et al.
Publicado: (2021) -
RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma
por: Liu, Yuenan, et al.
Publicado: (2019) -
ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma
por: Xu, Tianbo, et al.
Publicado: (2020) -
TIMP1 Indicates Poor Prognosis of Renal Cell Carcinoma and Accelerates Tumorigenesis via EMT Signaling Pathway
por: Shou, Yi, et al.
Publicado: (2022) -
Low Expression Levels of SLC22A12 Indicates a Poor Prognosis and Progresses Clear Cell Renal Cell Carcinoma
por: Xu, Jiaju, et al.
Publicado: (2021)